Evidence map›Paper›PMID 36792619›Full record

ArticleScientific reports2023

Cytotoxic and chemomodulatory effects of Phyllanthus niruri in MCF-7 and MCF-7

Ola E Abdel-Sattar, Rasha Mosa Allam, Ahmed M Al-Abd, Bharathi Avula, Kumar Katragunta, Ikhlas A Khan, Ahmed M El-Desoky, Shanaz O Mohamed, Ali El-Halawany, Essam Abdel-Sattar and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Anticancer activity prediction ofJournal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ola E Abdel-SattarPharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr El Aini St., Cairo, 11562, Egypt.
Rasha Mosa AllamPharmacology Department, Medical and Clinical Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.
Ahmed M Al-AbdPharmacology Department, Medical and Clinical Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.
Bharathi AvulaNational Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
Kumar KatraguntaNational Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
Ikhlas A KhanNational Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
Ahmed M El-DesokyDepartment of Molecular Biology, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City (USC), Sadat City, 32958, Egypt.
Shanaz O MohamedSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, 11700, Gelugor, Penang, Malaysia.
Ali El-HalawanyPharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr El Aini St., Cairo, 11562, Egypt.
Essam Abdel-SattarPharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr El Aini St., Cairo, 11562, Egypt. essam.abdelsattar@pharma.cu.edu.eg.ORCID 0000-0002-0617-1420
Meselhy R MeselhyPharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr El Aini St., Cairo, 11562, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The members of the genus Phyllanthus have long been used in the treatment of a broad spectrum of diseases. They exhibited antiproliferative activity against various human cancer cell lines. Breast cancer is the most diagnosed cancer and a leading cause of cancer death among women. Doxorubicin (DOX) is an anticancer agent used to treat breast cancer despite its significant cardiotoxicity along with resistance development. Therefore, this study was designed to assess the potential cytotoxicity of P. niruri extracts (and fractions) alone and in combination with DOX against naïve (MCF-7) and doxorubicin-resistant breast cancer cell lines (MCF-7

Indexed as

Antineoplastic AgentsBreast NeoplasmsPhyllanthusDoxorubicinDrug Resistance, NeoplasmFemaleHumansMCF-7 CellsAntineoplastic AgentsDoxorubicin

Identifiers

PMID36792619
PMCPMC9932073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.